254 related articles for article (PubMed ID: 29343697)
1. Effluent and serum protein N-glycosylation is associated with inflammation and peritoneal membrane transport characteristics in peritoneal dialysis patients.
Ferrantelli E; Farhat K; Ederveen ALH; Reiding KR; Beelen RHJ; van Ittersum FJ; Wuhrer M; Dotz V
Sci Rep; 2018 Jan; 8(1):979. PubMed ID: 29343697
[TBL] [Abstract][Full Text] [Related]
2. Factors increasing severity of peritonitis in long-term peritoneal dialysis patients.
Park MS
Adv Ren Replace Ther; 1998 Jul; 5(3):185-93. PubMed ID: 9686629
[TBL] [Abstract][Full Text] [Related]
3. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.
Rippe B; Simonsen O; Heimbürger O; Christensson A; Haraldsson B; Stelin G; Weiss L; Nielsen FD; Bro S; Friedberg M; Wieslander A
Kidney Int; 2001 Jan; 59(1):348-57. PubMed ID: 11135090
[TBL] [Abstract][Full Text] [Related]
4. Peritoneal solute transport and inflammation.
Davies SJ
Am J Kidney Dis; 2014 Dec; 64(6):978-86. PubMed ID: 25176170
[TBL] [Abstract][Full Text] [Related]
5. Peritoneal inflammation and fibrosis in C-reactive protein transgenic mice undergoing peritoneal dialysis solution treatment.
Poon PY; Lan HY; Kwan BC; Huang XR; Chow KM; Szeto CC; Li PK
Nephrology (Carlton); 2017 Feb; 22(2):125-132. PubMed ID: 26857687
[TBL] [Abstract][Full Text] [Related]
6. Biocompatible Solutions and Long-Term Changes in Peritoneal Solute Transport.
Elphick EH; Teece L; Chess JA; Do JY; Kim YL; Lee HB; Davison SN; Topley N; Davies SJ; Lambie M
Clin J Am Soc Nephrol; 2018 Oct; 13(10):1526-1533. PubMed ID: 30171050
[TBL] [Abstract][Full Text] [Related]
7. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis.
Krediet RT
Perit Dial Int; 2001; 21(6):560-7. PubMed ID: 11783764
[TBL] [Abstract][Full Text] [Related]
8. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991].
Nau B; Schmitt CP; Almeida M; Arbeiter K; Ardissino G; Bonzel KE; Edefonti A; Fischbach M; Haluany K; Misselwitz J; Kemper MJ; Rönnholm K; Wygoda S; Schaefer F;
BMC Nephrol; 2004 Oct; 5():14. PubMed ID: 15485574
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory factors for hypoalbuminemia in Japanese peritoneal dialysis patients.
Shioya M; Yoshida T; Kasai K; Furuya R; Kato A; Mori N; Matsumoto Y; Kumagai H
Nephrology (Carlton); 2013 Aug; 18(8):539-44. PubMed ID: 23718260
[TBL] [Abstract][Full Text] [Related]
10. Peritoneal Protein Losses Depend on More Than Just Peritoneal Dialysis Modality and Peritoneal Membrane Transporter Status.
Yoowannakul S; Harris LS; Davenport A
Ther Apher Dial; 2018 Apr; 22(2):171-177. PubMed ID: 29314721
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo analysis of dialysis effluent-derived mesothelial cells as an approach to unveiling the mechanism of peritoneal membrane failure.
López-Cabrera M; Aguilera A; Aroeira LS; Ramírez-Huesca M; Pérez-Lozano ML; Jiménez-Heffernan JA; Bajo MA; del Peso G; Sánchez-Tomero JA; Selgas R
Perit Dial Int; 2006; 26(1):26-34. PubMed ID: 16538870
[TBL] [Abstract][Full Text] [Related]
12. Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions.
Parikova A; Zweers MM; Struijk DG; Krediet RT
Adv Perit Dial; 2003; 19():186-90. PubMed ID: 14763059
[TBL] [Abstract][Full Text] [Related]
13. Dialysate cancer antigen 125 in long-term peritoneal dialysis patients.
Ditsawanon P; Supasyndh O; Aramwit P
Clin Exp Nephrol; 2014 Feb; 18(1):10-5. PubMed ID: 23757048
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic role of peritoneal CA 125 in peritoneal dialysis patients presenting with acute peritonitis.
Panorchan K; Davenport A
BMC Nephrol; 2014 Sep; 15():149. PubMed ID: 25217152
[TBL] [Abstract][Full Text] [Related]
15. Acute phase inflammation is characterized by rapid changes in plasma/peritoneal fluid N-glycosylation in mice.
Rombouts Y; Jónasdóttir HS; Hipgrave Ederveen AL; Reiding KR; Jansen BC; Freysdottir J; Hardardottir I; Ioan-Facsinay A; Giera M; Wuhrer M
Glycoconj J; 2016 Jun; 33(3):457-70. PubMed ID: 26924641
[TBL] [Abstract][Full Text] [Related]
16. Relationship between dialysate oxidized protein and peritoneal membrane transport properties in patients on peritoneal dialysis.
Latcha S; Hong S; Gibbons N; Kohn N; Mattana J
Nephrol Dial Transplant; 2008 Oct; 23(10):3295-301. PubMed ID: 18443211
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor.
Aroeira LS; Aguilera A; Selgas R; Ramírez-Huesca M; Pérez-Lozano ML; Cirugeda A; Bajo MA; del Peso G; Sánchez-Tomero JA; Jiménez-Heffernan JA; López-Cabrera M
Am J Kidney Dis; 2005 Nov; 46(5):938-48. PubMed ID: 16253736
[TBL] [Abstract][Full Text] [Related]
18. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds.
Miyata T; Horie K; Ueda Y; Fujita Y; Izuhara Y; Hirano H; Uchida K; Saito A; van Ypersele de Strihou C; Kurokawa K
Kidney Int; 2000 Jul; 58(1):425-35. PubMed ID: 10886591
[TBL] [Abstract][Full Text] [Related]
19. The renin-angiotensin-aldosterone system in peritoneal dialysis: is what is good for the kidney also good for the peritoneum?
Nessim SJ; Perl J; Bargman JM
Kidney Int; 2010 Jul; 78(1):23-8. PubMed ID: 20336052
[TBL] [Abstract][Full Text] [Related]
20. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
